Changes in baseline T-cell activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Subjects:

Effects of TGF-β1 on the expression of fibrosis indicators in HBdSMCs and the effects of MEL on the expression of fibrosis indicators in HBdSMCs induced by TGF-β1. by Yang Zhang (30734)

Mean liver weight (g) (A), liver weight/body ratio (B), hepatic triglyceride (mg/g) (C) and hepatic steatosis quantification (% area) (D) upon completion of the treatment phase. by Elsie D. Oduor (22521785)

Hepatosomatic index % (a); Spleen somatic index % (b) in tilapia in different experimental groups. by Sinthia Kabir Mumu (17705902)

Subjects:

Lysozyme activity in different experimental groups in tilapia. by Sinthia Kabir Mumu (17705902)

Subjects:

Plasma cortisol concentration in different experimental groups in tilapia. by Sinthia Kabir Mumu (17705902)

Subjects:

Blood glucose concentrations of tilapia in different experimental groups (control, stress, prevention, and treatment) were examined. by Sinthia Kabir Mumu (17705902)

Subjects:

Fig 4 - by Sinthia Kabir Mumu (17705902)

Subjects:

Mean SARS-CoV-2 viral load log 10 between groups. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Differential gene expression assay EC₅₀ values in Huh-7 cells and PHH. by Xuan G. Luong (9761423)

Changes in baseline T-cell exhaustion, monocyte activation and platelet activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Subjects:

50 ways to trace your veteran: increasing response rates can be cheap and effective by Nicola Townsend Fear (14297773)

Subjects:

Meta-analytical results of secondary outcomes. by Maria-Sophie Brueckle (13816408)

Subjects:

Flowchart of evidence selection based on PRISMA. by Maria-Sophie Brueckle (13816408)

Subjects:

Study characteristics. by Maria-Sophie Brueckle (13816408)

Subjects:

Forest plots of primary outcomes. by Maria-Sophie Brueckle (13816408)

Subjects:

Extracted ion chromatogram of azoxystrobin 50 ppb, injection volume of 2, 5, and 25 μL. by Ekramy Halawa (11785086)

Open data. by Larissa Brazolotto Ferreira (17671168)

Subjects:

DataSheet_2_Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis.xlsx by Qinggan Ni (14835463)

DataSheet_3_Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis.xlsx by Qinggan Ni (14835463)